Annovis Bio, Inc.
ANVS
$1.57
-$0.07-4.27%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.74M | 1.70M | 1.98M | 1.29M | 1.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.73M | 4.39M | 7.76M | 7.81M | 10.44M |
| Operating Income | -6.73M | -4.39M | -7.76M | -7.81M | -10.44M |
| Income Before Tax | -5.86M | -12.64M | -5.02M | -1.07M | -22.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.86M | -12.64M | -5.02M | -1.07M | -22.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.86M | -12.64M | -5.02M | -1.07M | -22.21M |
| EBIT | -6.73M | -4.39M | -7.76M | -7.81M | -10.44M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.43 | -0.97 | -0.44 | -0.10 | -2.24 |
| Normalized Basic EPS | -0.27 | -0.61 | -0.28 | -0.06 | -1.40 |
| EPS Diluted | -0.48 | -0.97 | -0.44 | -1.44 | -2.24 |
| Normalized Diluted EPS | -0.27 | -0.61 | -0.28 | -0.06 | -1.40 |
| Average Basic Shares Outstanding | 13.79M | 12.98M | 11.31M | 10.63M | 9.93M |
| Average Diluted Shares Outstanding | 13.79M | 12.98M | 11.31M | 10.82M | 9.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |